Company Filing History:
Years Active: 1997
Title: Homayon Ghiasi: Innovator in Immunotherapy
Introduction
Homayon Ghiasi is a prominent inventor based in Los Angeles, CA. He has made significant contributions to the field of immunotherapy, particularly in the treatment of Herpes Simplex Virus (HSV) infections. With a total of 3 patents to his name, Ghiasi's work is paving the way for innovative therapeutic solutions.
Latest Patents
One of Ghiasi's latest patents is focused on immunotherapy for recurrent HSV infections. This invention involves a local therapeutic or prophylactic vaccine for the eye, which comprises one or more recombinant HSV-1 glycoproteins or proteins, specifically gB and gD, combined with at least one adjuvant. This approach aims to reduce the incidence of primary HSV-1 infection and decrease spontaneous HSV-1 ocular shedding, ultimately controlling recurrent corneal disease. Another notable patent is a process for the expression of herpes simplex virus type 1 glycoprotein I. This process details how to obtain HSV-1 glycoprotein I (gI) from cells infected or transformed with a recombinant Baculovirus. The produced gI is isolated and purified for use in immunotherapy against HSV infections.
Career Highlights
Homayon Ghiasi is affiliated with Cedars-Sinai Medical Center, where he continues to advance his research and innovations in immunotherapy. His work is instrumental in developing new treatment options for HSV infections, which can have significant impacts on patient care.
Collaborations
Some of Ghiasi's notable coworkers include Anthony B. Nesburn and Steven L. Wechsler. Their collaborative efforts contribute to the ongoing research and development in the field of immunotherapy.
Conclusion
Homayon Ghiasi's innovative work in immunotherapy showcases his commitment to advancing medical science and improving treatment options for HSV infections. His contributions are vital in the ongoing battle against viral diseases, and his patents reflect a promising future in this area of research.